Airway surface liquid pH in paediatric patients with cystic fibrosis

Vasquez-Perez, Amalui; Bosque-García, Montserrat; Rudi-Sola, Nuria; Parada-Ricart, Ester; Closa-Monasterolo, Ricardo.
Rev. patol. respir ; 26(4)oct.-dic. 2023. ilus, tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-228616

Documentos relacionados

  1. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
  2. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension study.
  3. Comprehensive Assessment of <i>CFTR</i> Modulators' Therapeutic Efficiency for N1303K Variant.
  4. Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties <i>via</i> hydration.
  5. Pathogenic Variants and Genotypes of the <i>CFTR</i> Gene in Russian Men with Cystic Fibrosis and CBAVD Syndrome.
  6. Real world outcomes of CFTR modulator therapy in Australian adults and children.
  7. High frequency of complex CFTR alleles associated with c.1521_1523delCTT (F508del) in Russian cystic fibrosis patients.
  8. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two <i>F508del</i> Alleles.
  9. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
  10. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.